Role of tolvaptan in acute decompensated heart failure

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 5, 2008, Pages 601-608

  Ho, Jennifer E ^a   Teerlink, John R ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Heart failure; Pharmacology; Tolvaptan; Vasopressin

Indexed keywords

ARGIPRESSIN; CONIVAPTAN; DIURETIC AGENT; FUROSEMIDE; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; NESIRITIDE; NEUROHORMONE; PLACEBO; TEZOSENTAN; TOLVAPTAN; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR;

ACUTE HEART FAILURE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DEHYDRATION; DIURESIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTROL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EVIDENCE BASED MEDICINE; HORMONE BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERNATREMIA; HYPONATREMIA; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PATHOPHYSIOLOGY; PHARMACODYNAMICS; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; TACHYCARDIA; THIRST; UNITED STATES; UNSPECIFIED SIDE EFFECT; WATER DEPRIVATION; XEROSTOMIA; ACUTE DISEASE; CAUSE OF DEATH; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; HEART FAILURE; MALE; MAXIMUM TOLERATED DOSE; MORTALITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ACUTE DISEASE; BENZAZEPINES; CAUSE OF DEATH; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASOPRESSIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 47149107422     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.5.601     Document Type: Article

References (51)

1. Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail. Rev. 9(3), 179-185 (2004).
2. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82(5), 1724-1729 (1990).
3. Domanski M, Norman J, Pitt B et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 42(4), 705-708 (2003).
4. Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am. J. Cardiol. 80(4), 519-522 (1997).
5. De Luca L, Orlandi C, Udelson JE, Fedele F, Gheorghiade M. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. Am. J. Cardiol. 96(12A), L24-L33 (2005).
6. Klein L, O'Connor CM, Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111(19), 2454-2460 (2005).
7. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293(5), 572-580 (2005).
8. Yancy C. Climbing the mountain of acute decompensated heart failure: the EVEREST trials. JAMA 297(12), 1374-1376 (2007).
9. Teerlink JR, Massie BM. Nesiritide and worsening of renal function: the emperor's new clothes? Circulation 111(12), 1459-1461 (2005).
10. Elkayam U, Tasissa G, Binanay C et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am. Heart J. 153(1), 98-104 (2007).
11. Weber KT. Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J. Am. Coll. Cardiol. 44(6), 1308-1310 (2004).
12. Felker GM, Benza RL, Chandler AB et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J. Am. Coll. Cardiol. 41(6), 997-1003 (2003).
13. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111(12), 1487-1491 (2005).
14. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293(15), 1900-1905 (2005).
15. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA 296(12), 1465-1466 (2006).
16. Costanzo MR, Guglin ME, Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 49(6), 675-683 (2007).
17. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail. 8(1), 105-110 (2006).
18. Follath F, Cleland JG, just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360(9328), 196-202 (2002).
19. Packer M, Colucci WS, Fisher L et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure results with levosimendan in the REVIVE-1 study [abstract]. J. Card. Fail. 9, S61 (2003).
20. Mebazaa A, Nieminen MS, Packer M et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297(17), 1883-1891 (2007).
21. McMurray JJ, Teerlink JR, Cotter G et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298(17), 2009-2019 (2007).
22. Rouleau JL, Packer M, Moye L et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll. Cardiol. 24(3), 583-591 (1994).
23. Palm C, Pistrosch F, Herbrig K, Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am. J. Med. 119(7 Suppl. 1), S87-S92 (2006).
24. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol. 46(10), 1785-1791 (2005).
25. 2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104(20), 2417-2423 (2001).
26. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287(3), 860-867 (1998).
27. Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide avp antagonist, during ascending single-dose studies in healthy subjects. J. Clin. Pharmacol. 47(12), 1498-1507 (2007).
28. Costello-Boerrigter L, Smith W, Boerrigter G et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol. 290(2), F273-F278 (2006).
29. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 341(8), 577-585 (1999).
30. Robinson A, Verbalis J. Posterior pituitary. In: Williams Textbook of Endocrinology (11th Edition). Kronenberg HM (Ed.). Saunders Elsevier, PA, USA, 264 (2008).
31. 1 subtype receptors. Circ. Res. 69(1), 239-245 (1991).
32. 1A) receptor. Eur. J. Pharmacol. 391(1-2), 39-48 (2000).
33. 2-vasopressinergic receptors. Am. J. Physiol. 255(2 Pt 2), H261-H265 (1988).
34. 2 receptor antagonist. Bioorg. Med. Chem. 7(8), 1743-1754 (1999).
35. Hauptman P, Zimmer C, Udelson J et al. Comparison of two closes and dosing regimens of tolvaptan in congestive heart failure. J. Cardiovasc. Pharmacol. 46(5), 609-614 (2005).
36. 2 vasopressin antacgonist protects against the decline in renal function observed with loop diuretic therapy. J. Card. Fail. 9, 36 (2003).
37. 2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in racs. J. Pharmacol. Exp. Ther. 292(1), 288-294 (2000).
38. Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J. Cardiovasc. Pharmacol. 50(2), 213-222 (2007).
39. Shoaf SE, Elizari MV, Wang Z et al. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J. Cardiovasc. Pharmacol. Ther. 10(3), 165-171 (2005).
40. 2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107(21), 2690-2696 (2003).
41. Gheorghiade M, Gattis W, O'Connor C et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart Wive: a randomized controlled trial. JAMA 291(16), 1963-1971 (2004).
42. Udelson J, McGrew F, Flores E et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 49(22), 2151-2159 (2007).
43. Gheorghiade M, Gattis W. Barbagelata A et al. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am. Heart J. 145(2 Suppl.), S51-S54 (2003).
44. Rossi J, Bayram M, Udelson J et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card. Care 9(2), 82-86 (2007).
45. 2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. 97(7), 1064-1067 (2006).
46. Udelson J, Orlandi C, Ouyang J et al. Acute hemodynamic effects of tolvaptan, a vasopressin v2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE international, multicenter, randomized, placebo-controlled trial. J. Card. Fail. 13(9), 793-794 (2007).
47. 2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355(20), 2099-2112 (2006).
48. Gheorghiade M, Orlandi C, Burnett J et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin aAtagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J. Card Fail. 11 (4), 260-269 (2005).
49. Gheorghiade M, Konstam M, Burnett J et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297(12), 1332-1343 (2007).
50. Konstam M, Gheorghiade M, Burnett J et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12), 1319-1331 (2007).
51. 2 receptor antagonist. In: Bioorganic & Medicinal Chemistry. Elsevier, NJ, USA, 12 (1999).